Novo secures Dicernas RNAi liver assetsDanish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets. more ➔
EU with poor success in fighting superbugs The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance. more ➔
Cellectis presents way to safer CAR-TsResearchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells. more ➔
Magenta Therapeutics exercises ATAC licenc...Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AGs anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC). more ➔
Vaximm goes East for cancer vaccine deal Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines. more ➔
Abcam buys Expedeons immunology business Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business. more ➔
SciRhom targets autoimmunity switch Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2. more ➔
AMR: ENABLE selects Mutabilis candidateA drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI). more ➔
NSCLC: Bemcentinib + anti-PD1 triple PFS Bergen Bio ASAs Axl kinase blocker bemcentinib in combination with MSDs pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC). more ➔
Transposase makes CAR-T production cheaperGerman researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies. more ➔
